This company has been acquired
89bio (ETNB) Stock Overview
A clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
ETNB Community Fair Values
Create NarrativeSee what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.
89bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$14.84 |
| 52 Week High | US$15.06 |
| 52 Week Low | US$4.16 |
| Beta | 1.26 |
| 1 Month Change | 0.95% |
| 3 Month Change | 56.21% |
| 1 Year Change | 85.73% |
| 3 Year Change | 59.40% |
| 5 Year Change | -40.45% |
| Change since IPO | -28.65% |
Recent News & Updates
89bio: Pegozafermin MASH Drug Advancement Nets Roche Acquisition
Sep 18Is 89bio (NASDAQ:ETNB) A Risky Investment?
May 22
89bio: Primary Asset Targeting 2 Potential Indications And Is In Late-Stage Development
Apr 17Recent updates
89bio: Pegozafermin MASH Drug Advancement Nets Roche Acquisition
Sep 18Is 89bio (NASDAQ:ETNB) A Risky Investment?
May 2289bio: Primary Asset Targeting 2 Potential Indications And Is In Late-Stage Development
Apr 1789bio's Pegozafermin Is Now Gaining Momentum
Jan 3089bio: Advancement Of Pegozafermin For SHTG Is Another Path Forward
Jan 1389bio: Surviving A Competitive Space - For Now
Oct 29Health Check: How Prudently Does 89bio (NASDAQ:ETNB) Use Debt?
Sep 2689bio: Bullish In Light Of Further MOA Being Established By Peer
Aug 0789bio: Pegozafermin Could Be A Game-Changer For Liver Disease - Strong Buy
May 2389bio Still Has A Chance As NASH Race Heats Up
Oct 0689bio completes enrollment in phase 2 trial for NASH treatment
Aug 1889Bio rallies on Deep Track Capital disclosing 10% stake
Jul 07Shareholder Returns
| ETNB | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.3% | 3.1% | 0.5% |
| 1Y | 85.7% | 3.9% | 20.1% |
Return vs Industry: ETNB exceeded the US Biotechs industry which returned 3.9% over the past year.
Return vs Market: ETNB exceeded the US Market which returned 18.7% over the past year.
Price Volatility
| ETNB volatility | |
|---|---|
| ETNB Average Weekly Movement | 24.2% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ETNB's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ETNB's weekly volatility has increased from 16% to 24% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 93 | Rohan Palekar | www.89bio.com |
89bio, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of metabolic dysfunction-associated steatohepatitis and hypertriglyceridemia. The company was founded in 2018 and is headquartered in San Francisco, California.
89bio, Inc. Fundamentals Summary
| ETNB fundamental statistics | |
|---|---|
| Market cap | US$2.31b |
| Earnings (TTM) | -US$450.21m |
| Revenue (TTM) | n/a |
Is ETNB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ETNB income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$450.21m |
| Earnings | -US$450.21m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.89 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 6.9% |
How did ETNB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/29 02:02 |
| End of Day Share Price | 2025/10/29 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
89bio, Inc. is covered by 17 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Zemansky | BofA Global Research |
| Kristen Kluska | Cantor Fitzgerald & Co. |
| Steven Seedhouse | Cantor Fitzgerald & Co. |